Alzheimer's Disease Trial, Recruiting NCT07531732 Sponsor: Assistance Publique - Hôpitaux de Paris Condition: Alzheimer's Disease
Back to Alzheimers Disease

Alzheimer's Disease Trial, Recruiting

NCT07531732
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with a possible or probable behavioural form of frontotemporal dementia (a type of dementia that mainly affects behaviour and personality), based on a specific set of medical guidelines from 2011
  • People who have been diagnosed with Alzheimer's disease, confirmed using brain or biological markers, based on a specific set of medical guidelines from 2018
  • People whose score on a standard memory and thinking test (called the MMSE) is 20 or above, indicating mild rather than severe cognitive difficulties
  • People aged between 50 and 80 years old
  • People who, in the opinion of the trial investigator, can read and write in French well enough to complete the study tasks

Who may not be able to join:

  • People who have moderate to severe difficulties with language, specifically those who score 32 or below on a standard picture-naming test (called the DO 40)
  • People who, in the opinion of the trial investigator, are unable to use or complete tasks on a computer
  • People who have other neurological conditions, such as epilepsy, Lewy body disease, or vascular dementia (a type of dementia caused by reduced blood flow to the brain)
  • People who have certain psychiatric conditions, including bipolar disorder, schizophrenia, or a current major depressive episode
  • People who have vision problems that have not been corrected with glasses or other means

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +33 (0) 1 40 05 49 54

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 April 2026
Est. completion
1 December 2027

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Metacognitive efficiency during facial emotion recognition (Mratio)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov